354 related articles for article (PubMed ID: 20368400)
1. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.
Hafner V; Czock D; Burhenne J; Riedel KD; Bommer J; Mikus G; Machleidt C; Weinreich T; Haefeli WE
Antimicrob Agents Chemother; 2010 Jun; 54(6):2596-602. PubMed ID: 20368400
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis.
Luke DR; Wood ND; Tomaszewski KE; Damle B
Nephrol Dial Transplant; 2012 Mar; 27(3):1207-12. PubMed ID: 21868395
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.
Kiser TH; Fish DN; Aquilante CL; Rower JE; Wempe MF; MacLaren R; Teitelbaum I
Crit Care; 2015 Feb; 19(1):32. PubMed ID: 25645660
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.
Abel S; Allan R; Gandelman K; Tomaszewski K; Webb DJ; Wood ND
Clin Drug Investig; 2008; 28(7):409-20. PubMed ID: 18544001
[TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment.
Hoover RK; Alcorn H; Lawrence L; Paulson SK; Quintas M; Luke DR; Cammarata SK
J Clin Pharmacol; 2018 Jun; 58(6):814-822. PubMed ID: 29578585
[TBL] [Abstract][Full Text] [Related]
6. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).
Luke DR; Tomaszewski K; Damle B; Schlamm HT
J Pharm Sci; 2010 Aug; 99(8):3291-301. PubMed ID: 20213839
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients.
Peng LW; Lien YH
Am J Kidney Dis; 2005 Jan; 45(1):162-6. PubMed ID: 15696456
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration.
Fuhrmann V; Schenk P; Jaeger W; Miksits M; Kneidinger N; Warszawska J; Holzinger U; Kitzberger R; Thalhammer F
J Antimicrob Chemother; 2007 Nov; 60(5):1085-90. PubMed ID: 17855725
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of intravenous voriconazole in patients with compromised renal function.
Lilly CM; Welch VL; Mayer T; Ranauro P; Meisner J; Luke DR
BMC Infect Dis; 2013 Jan; 13():14. PubMed ID: 23320795
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
[TBL] [Abstract][Full Text] [Related]
12. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient.
Robatel C; Rusca M; Padoin C; Marchetti O; Liaudet L; Buclin T
J Antimicrob Chemother; 2004 Jul; 54(1):269-70. PubMed ID: 15175271
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.
von Mach MA; Burhenne J; Weilemann LS
BMC Clin Pharmacol; 2006 Sep; 6():6. PubMed ID: 16981986
[TBL] [Abstract][Full Text] [Related]
15. Effect of Cumulative Intravenous Voriconazole Dose on Renal Function in Hematological Patients.
Yasu T; Konuma T; Kuroda S; Takahashi S; Tojo A
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987145
[TBL] [Abstract][Full Text] [Related]
16. Kolliphor® HS 15-cyclodextrin Complex for the Delivery of Voriconazole: Preparation, Characterization, and Antifungal Activity.
Li Y; Zhu C; Wu H; Pan H; Liu H
Curr Drug Metab; 2020; 21(5):379-389. PubMed ID: 32432999
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole injection may induce delayed methotrexate excretion: a case report and experimental study.
Watahiki D; Saito D; Nishida N; Tsuri H; Nomura K; Adachi Y; Taguchi M
J Pharm Health Care Sci; 2022 Mar; 8(1):9. PubMed ID: 35351207
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of voriconazole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses.
Colitz CM; Latimer FG; Cheng H; Chan KK; Reed SM; Pennick GJ
Am J Vet Res; 2007 Oct; 68(10):1115-21. PubMed ID: 17916020
[TBL] [Abstract][Full Text] [Related]
19. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients.
Mohr JF; Finkel KW; Rex JH; Rodriguez JR; Leitz GJ; Ostrosky-Zeichner L
Antimicrob Agents Chemother; 2004 Aug; 48(8):3151-3. PubMed ID: 15273137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
